RHRex Wan-Hin Hui

Rex Wan-Hin Hui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rex Wan-Hin Hui has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Prospect of Novel Therapies for Functional Cure in Chronic Hepatitis B

    by Karen Cheuk‐Ying Ho, Rex Wan‐Hin Hui, Lung‐Yi Mak, Man‐Fung Yuen

    Background: Chronic hepatitis B (CHB) remains a major global health problem. Functional cure is defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with undetectable HBV DNA 24 weeks after cessation of therapy. It has emerged as a clinically meaningful endpoint, associated with regression of liver fibrosis, reduced hepatocellular carcinoma (HCC) risk, and a lower treatment burden. However, current CHB therapies, including nucleos(t)ide analogues (NUCs) and pegylated interferon‐α (Peg‐IFNα), rarely lead to functional cure despite adequate viral suppression, leading to a notable portion of patients remaining at risk for adverse liver‐related outcomes, including hepatic decompensation and HCC. Hence, novel therapeutic agents are aimed at accelerating towards functional cure. They are categorized as virus‐targeting and immunomodulatory therapies. Methods: This review summarizes the clinical evidence for emerging therapies aimed at acheiving functional cure, with a particular focus on RNA‐targeting therapies. It also discusses practical considerations relevant to treatment selection. Results: Among these novel therapies, RNA‐targeting therapies are currently the most promising, with bepirovirsen (an unconjugated antisense oligonucleotide) standing out as the only agent completed in Phase III study showing efficacious results. Combination regimens that use RNA‐targeting therapies as backbone are increasingly pursued, leveraging potential synergistic effects to achieve higher rates of HBsAg seroclearance. Conclusion: RNA‐targetting therapies and combination regimens offer promising approaches in attaining functional cure in CHB. Further research should emphasize on the long‐term efficacy and safety for these novel agents.

  • Impact of Cardiometabolic Risk Factors Control on Cardiovascular–Kidney–Metabolic Axis in Chronic Hepatitis B

    by Karen Cheuk‐Ying Ho, Rex Wan‐Hin Hui, Matthew Shing‐Hin Chung, Wai‐Kay Seto, Man‐Fung Yuen, Lung‐Yi Mak

    Background: The impact of cardiometabolic risk factors (CMRFs) on the cardiovascular–kidney–metabolic (CKM) axis in chronic hepatitis B (CHB) remains poorly defined. Methods: We conducted a prospective analysis enrolling patients with CHB who were on nucleos(t)ide analogues (NUCs). CMRFs were defined as per established criteria; poorly‐controlled CMRFs were defined with specific cut‐offs measured across 5 years. Study outcomes include fibrosis progression (liver stiffness [LS] increase by ≥ 20%), liver‐related events (LREs), chronic kidney disease (CKD) progression, major adverse cardiovascular events (MACE), and all‐cause mortality. Results: A total of 714 NUC‐treated patients (median age: 61.0 [54.5–66.7] years; 69.6% male; 90.5% undetectable HBV DNA, median NUCs duration of 14.1 [11.3–16.5] years) were followed up for 9.7 (7.2–10.2) years. LREs occurred in 112 (15.7%) patients, with annual incidence rate of 1.62 events per 100 person‐years. All‐cause mortality was observed in 86 (12%) patients, including 47 (6.6%) liver‐related mortality. The number or types of CMRFs did not display a linear positive relationship with adverse clinical outcomes. The presence of ≥ 1 poorly controlled CMRFs is independently associated with LREs (aHR: 2.001, 95% CI: 1.350–2.965), MACE (aHR: 1.042, 95% CI: 1.030–1.081), and all‐cause mortality (aHR: 2.082, 95% CI: 1.006–4.310), whereas patients having ≥ 2 and ≥ 3 poorly controlled CMRFs are independently associated with CKD progression (aOR: 1.887, 95% CI: 1.115–3.221) and fibrosis progression (aOR: 1.624, 95% CI: 1.164–2.266), respectively. The results remain robust in patients without advanced fibrosis (LS ≤ 10 kPa) at baseline. Conclusion: Active optimization of CMRFs should be an integral component of CHB management in addition to NUCs therapy.

  • Obesity and Mortality in V-V ECMO: Patient Heterogeneity Explains the Conflicting Findings

    by Wincy Ng, Ka-Chun Leung, Rex Wan-Hin Hui, Pauline Yeung Ng, Chun-Wai Ngai, Simon Wai-Ching Sin

    Was not provided for this article.

  • Occult hepatitis B virus infection

    by Lung-Yi Mak, Rex Wan-Hin Hui, Teresa Pollicino, Markus Cornberg, Robert Gish, Ira Jacobson, Patrick T. Kennedy, Wai-Kay Seto, Giovanni Raimondo, Man-Fung Yuen

  • Open Access

    HBsAg isoforms predict HBsAg seroclearance and finite treatment in patients with chronic hepatitis B after cessation of long-term nucleos(t)ide analogs

    by Lung-Yi Mak, Mark Anderson, Rex Wan-Hin Hui, Tiffany Fortney, Karen Cheuk-Ying Ho, Rene Geissler, James Fung, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen

  • Droplet Digital PCR Measurement of HBV DNA in On-Treatment Chronic HBV Patients: Association With HCC Development and Outcomes.

    by Rex Wan-Hin Hui, Danny Ka-Ho Wong, James Fung, Ka-Shing Cheung, Wai-Kay Seto, Lung-Yi Mak, Man-Fung Yuen

    Low-level residual viremia can be present in chronic hepatitis B (CHB) patients on nucleos(t)ide analogues (NUCs). Due to the detection limits of current HBV DNA assays, the association between residual viremia and HBV-related HCC has not been well studied. This study included NUC-treated HBV-related HCC patients with unquantifiable serum HBV DNA by the conventional Cobas-Taqman assay (< 20 IU/mL) at HCC diagnosis. The HCC patients were matched in a 1:1 ratio with NUC-treated non-HCC controls. Serum samples at the time of HCC diagnosis, 1 year before, and 2 years before diagnosis were retrospectively retrieved and tested for residual viremia by a validated high-sensitivity droplet digital polymerase chain reaction assay (lower limit of detection 1.6 IU/mL). Among 208 patients (104 HCC vs. 104 controls; mean age 63.1, 80.8% male, 54.3% cirrhosis), residual viremia within 2 years was observed in 82.7% of HCC patients and 49.0% of controls (p < 0.001), and was independently associated with HCC occurrence (OR 7.243, 95% CI 1.862-28.170, p = 0.004). In HCC patients, residual viremia was associated with histological microvascular invasion (44.4% vs. 9.1% in patients without residual viremia, p = 0.033) and lower probability of presenting with Barcelona Clinic Liver Cancer stage 0 HCC (OR 0.281, 95% CI 0.094-0.838, p = 0.023). After median follow-up for 7.2 years, residual viremia within 2 years before HCC diagnosis was independently associated with liver-related mortality (HR 4.472, 95% CI 1.212-16.504, p = 0.025). Residual viremia in NUC-treated CHB patients is associated with a higher risk of HCC development, more advanced tumour staging and poorer outcomes. High-sensitivity HBV DNA assays may be utilized for monitoring in NUC treatment.

  • Adopting the lancet commission definition of clinical obesity in metabolic dysfunction-associated steatotic liver disease (MASLD)

    by Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Chi-Ho Lee, David Tak-Wai Lui, Man-Fung Yuen, Wai-Kay Seto, Lung-Yi Mak

    Background The Lancet Diabetes & Endocrinology Commission proposed a new definition of clinical obesity. We applied clinical obesity in a cohort of Asian patients with metabolic dysfunction-associated steatotic liver disease (MASLD) to evaluate its associations with clinical outcomes. Methods We enrolled 642 MASLD patients with vibration-controlled transient elastography (VCTE) assessment. A subgroup of 254 patients underwent additional bioelectrical impedance analysis (BIA). The diagnosis of clinical obesity required fulfilment of both anthropometric and clinical criteria. At-risk metabolic dysfunction-associated steatohepatitis (MASH) was defined by FibroScan-AST (FAST) score. Major adverse cardiovascular events (MACE) were defined as a composite outcome of acute coronary syndrome or stroke. Results Among 642 MASLD patients (mean age 55.8 ± 12.5 years; 49.2% male, mean BMI 28.2 ± 4.7 kg/m2, 76% severe steatosis, 12.5% advanced fibrosis/cirrhosis [F3/F4]), 46.1% of patients fulfilled the diagnosis of clinical obesity. Clinical obesity criteria identified more patients with F3/F4 (20.6% vs 8.1%, p < 0.001), severe steatosis (83.8% vs 67.6%, p < 0.001), at-risk MASH (3.4% vs 0%, p = 0.056) and MACE (11.2% vs 2.7%, p = 0.006) compared with BMI-based criteria. Clinical obesity was an independent predictor of F3/F4 (OR 4.074, 95% CI 2.195–7.563, p < 0.001) and severe steatosis (OR 2.441, 95% CI 1.638–3.637, p < 0.001). Among patients with BIA, clinical obesity was associated with a lower appendicular skeletal muscle mass (27.0% vs 41.1%, P < 0.001) and a greater visceral fat index (15 vs 9, p < 0.001) compared with BMI-based criteria. Conclusion Clinical obesity criteria identified more MASLD patients with F3/F4, severe steatosis, at-risk MASH and MACE compared with BMI-based obesity criteria. It should be regularly utilized for prognostication in MASLD evaluation.


  • Open Access

    Prospective evaluation of artificial intelligence-assisted monitoring of the effective withdrawal time on adenoma detection

    by Thomas Ka Luen Lui, Carla Pui-Mei Lam, Vivien Wai-Man Tsui, Rex Wan-Hin Hui, Elvis Wai-Pan To, Loey Lung-Yi Mak, Michael Kwan-Lung Ko, Kevin Sze-Hang Liu, Cynthia Ka-Yin Hui, Jing Jia Liu, et al.

    Prospective evaluation of artificial intelligence-assisted monitoring of the effective withdrawal time on adenoma detection


  • Acute Pancreatitis After Intravesical BCG

    by Lok Yee Jane Lam, Rex Wan-Hin Hui, Ka-Yin Hui, Ming-Hong Choi, Tsz-Kin Kwok